



Corres. and Mail
BOX AF

RECEIVED

JUN 04 2002

TECH CENTER 1600/2900

AF/1617
#24/G
mp
6/14/02
N.E

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of : **Confirmation No. 1469**
Takeshi SAKAI et al. : **Docket No.00001/F-3511 PT-US-CPA**
Serial No. 09/269,711 : **Group Art Unit 1617**
Filed April 5, 1999 : **Examiner S. Wang**
APOPTOSIS INDUCING AGENT :

THE COMMISSIONER IS AUTHORIZED
TO CHARGE ANY DEFICIENCY IN THE
FEES FOR THIS PAPER TO DEPOSIT
ACCOUNT NO. 23-0975

AMENDMENT AFTER FINAL

Assistant Commissioner for Patents,
Washington, D.C. 20231

RESPONSE UNDER 37. CFR 1.116
EXPEDITED PROCEDURE
EXAMINING GROUP 1617

Sir:

Responsive to the Official Action dated March 19, 2002, please amend the above-
identified application as follows.

In the Claims:

Please amend the following claims as shown.

40. (Thrice Amended) A method of inducing apoptosis comprising administering an
apoptosis inducing agent which comprises glycerolipid as the effective component, to an
individual.

41. (Amended) The method as set forth in claim 40, wherein said glycerolipid is derived
from plants, microorganisms or animals.